• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

The Magic Mice of Regeneron

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
By STEPHEN GUILFOYLE
Mar 17, 2020 | 01:00 PM EDT
Stocks quotes in this article: REGN, SNY, MRNA, BNTX, PFE, GILD, TDOC, VEEV, CLX

Magic Mice

Regeneron (REGN) has apparently made some significant progress as it drives toward discovering and developing a multi-antibody cocktail meant to be administered either as a prophylactic agent ahead of exposure or as treatment if already infected.

"Ever hear of VelocImmune Mice? No? First you had to hear of Regeneron, which if you somehow make a living in science or in the financial markets, you may have. Otherwise, maybe not. These are mice that have been genetically modified to have themselves a human immune system, which gives the firm a head start as it goes about this important work. From these mice, the firm has identified hundreds of virus neutralizing antibodies. Antibodies from actual humans who have recovered from Covid-19 have also been recovered and isolated as well in order to maximize the firm's broad pool of prospects for use.

The firm has announced that from this pool the top two antibodies have been selected for this already mentioned "cocktail" treatment for this virus. The two selected have already demonstrated an affinity for the SARS-CoV-2 spike protein that provides a path for the virus to invade an individual.

Moving Forward

The firm's idea is to use this advanced technology to prepare manufacturing ready cell lines so that clinical scale production can start immediately. The firm adds that it is working with BARDA (Biomedical Advanced Research and Development Authority) which is an office within the U.S. Department of Health and Human Services to find ways to boost capacity.

Separately, Regeneron announced in collaboration with Sanofi (SNY) , a pharmaceutical headquartered in France, the initiation of U.S. clinical trials that will evaluate the candidate Kevzara in severely ill patients already hospitalized with a Covid-19 infection. This will be a two part trial involving 400 patients, the first part to evaluate the impact of the drug on patient needs related to fever as well as the need for supplemental oxygen. The second part would be aimed at longer term cases that involve oxygen provided through mechanical ventilation. Under the agreement, which has still not been finalized, Regeneron will lead the work in the U.S., and Sanofi will lead elsewhere.

On these developments, Regeneron CEO Dr. Leonard Schleifer appeared on the Fox Business Network on Tuesday morning. Schleifer said, "One has to come up with something rapidly that might attack the virus. That's the news today." He then added... "We are scaling up as fast as we can. We hope to be in clinical testing sometime in June." While encouraging, that still means that for a while, we are still on our own.

My Own Cocktail

This morning, in my Market Recon column at Real Money and Real Money Pro, I discussed progress being made by Moderna (MRNA) , a firm that has already gone into clinical testing for a potential messenger RNA based vaccine for the SARS-CoV-2 coronavirus, as well as progress made at BioNTech (BNTX) that is maybe a month behind in getting to trial if all goes well but is also working with partners in China and possibly Pfizer (PFE) in the U.S. if it can get there from a regulatory perspective. Is there room for these three names in my "virus group"?

Well, Moderna is already there, along with Gilead Sciences (GILD) , Teledoc (TDOC) , and Veeva Systems (VEEV) as well as a number of other plays outside of the medical/life sciences field, so I am pretty well covered. That said, I could definitely see bringing a few shares (not too many) of Regeneron on board the next time the algorithms include that name in a broad selloff. Not before. Oh, and every virus related investment needs to include Clorox (CLX) at this point. Just my opinion... but folks are learning to worry about germs again. That behavior will not die nearly as quickly as I hope this virus does.

(Clorox is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CLXL? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was  Long MRNA, GILD, TDOC, VEEV, CLX equity.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Biotechnology | Pharmaceuticals | Coronavirus

More from Investing

A Rush to Rotate Into Short-Squeeze Plays Is Roiling the Market

James "Rev Shark" DePorre
Jan 28, 2021 6:27 AM EST

The market is struggling with instability as a massive, short-squeeze movement continues. 'Good' stocks are being dumped by funds to pay for short-selling losses.

If You Think the Selling Started Yesterday, You Have a Short Memory

Helene Meisler
Jan 28, 2021 6:00 AM EST

A lot of what we saw on Wednesday has been in the works for a while now.

Emotions Run High as Indexes Slip

James "Rev Shark" DePorre
Jan 27, 2021 4:44 PM EST

I've raised a bit of cash, but it's still unclear what will emerge from here.

'Mortal Kombat' on the Market

Peter Tchir
Jan 27, 2021 3:54 PM EST

Let's pick apart the wild action in individual stocks -- especially GameStop -- and see what to expect going forward.

Butterflies Are Free: This GameStop Options Play Is Hardly Ever Seen

Timothy Collins
Jan 27, 2021 3:01 PM EST

I'll take a 66% risk-free rate of return in six months anytime.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST STEPHEN GUILFOYLE

    Cashing in Some More Chips at Stocks Under $10

    We're trimming a position for a big gain today.
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/27/2021

    The "correction" can be coming sooner than we thou...
  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login